<i>t</i>	<u>.</u>			点台等部層的 10 1111 2006						
FORM (REV. 7	PTO-13 <sup>(</sup> 7-2005)	390 (Modified) U.S. PATENT AND TRADEM	ARK OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER						
•		ANSMITTAL LETTER 1	ABLE0032US.NP							
	Γ	DESIGNATED/ELECTE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
C	NOC	ICERNING A SUBMISS	10/563,204							
	P	TONAL APPLICATION NO. PCT/GB2004/02909	INTERNATIONAL FILING DATE July 5, 2004	PRIORITY DATE CLAIMED July 4, 2003						
		INVENTION								
Phar	maceı	atical Compositions Comrpising	an Epitope of Platelet GPIHA Protein							
		IT(S) FOR DO/EO/US AK, Stanislaw Joseph et al.								
UKD.	AIIIA	.k., Stanisiaw Joseph et al.								
A a a li		array lith as health to the United Otate	Designated (Florand Office (DO/FO/HO) the	Collection of the collection o						
Applic	_	erewith submits to the United State	es Designated/Elected Office (DO/EO/US) the	following items and other information:						
1.			ms concerning a submission under 35 U.S.C.							
2.	$\boxtimes$	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.								
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.								
4.		The US has been elected (Article 31).								
5.		A copy of the International Applic	ation as filed (35 U.S.C. 371 (c)(2))							
		a.  is attached hereto (requ	ired only if not communicated by the Internati	ional Bureau).						
		b.  has been communicated	d by the International Bureau.							
		c.  is not required, as the a	pplication was filed in the United States Recei	iving Office (RO/US).						
6.		An English language translation of	of the International Application as filed (35 U.S	S.C. 371(c)(2)).						
		a.  is attached hereto.								
		b.  has been previously sub	bmitted under 35 U.S.C. 154(d)(4).							
7.		Amendments to the claims of the	International Application under PCT Article 19	9 (35 U.S.C. 371 (c)(3))						
		a.   are attached hereto (req	quired only if not communicated by the Interna	ational Bureau).						
		b.  have been communicate	ed by the International Bureau.							
		c.  have not been made; ho	owever, the time limit for making such amendn	ments has NOT expired.						
		d.   have not been made and	d will not be made.							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9.	$\boxtimes$	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).								
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).								
11.		A copy of the International Prelim	inary Examination Report (PCT/IPEA/409).							
12.		A copy of the International Search	າ Report (PCT/ISA/210).							
Ite	ems 1	3 to 23 below concern document	t(s) or information included:							
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
15.		A FIRST preliminary amendment.								
16.		A SECOND or SUBSEQUENT preliminary amendment.								
17.		A substitute specification.								
18.		A power of attorney and/or change of address letter.								
19.	$\boxtimes$	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.								
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).								
22.	$\boxtimes$	Express Mail Label No. EV	361212537US							

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ſ	U.S. APPLICATION	NO ( tee	.37 CER 1,5)	INTERNATIONAL A	APPLICATION N	10.	ATTORNEY'S DOC	KET NUMBER	
	M	94563209		PCT/GB0	4/02909		ABLE0032U	JS.NP	
	23. Other items or information:  1) Copy of Notification of Missing Requirements; 2) Response to Notification of Missing Requirements; 3) Paper copy of Amended Sequence Listing; and 4) Amendment under 37 CFR 1.825								
ŀ	The following	fees have been	submitted:	<del></del>			CALCULATIONS	PTO USE	
ı	24.						\$ \$0.00		
	25. ☐ Examination fee (37 CFR 1.492(c))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article \$0  All other situations. \$200						\$ \$0.00		
	26. ☐ Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0  Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the as an International Searching Authority\$100  International Search Report prepared by an ISA other than the US and provided to the previously communicated to the US by the IB\$400  All other situations\$500						\$ \$0.00		
	TOTAL	OF 24, 25 and	1 26 =				\$ \$0.00		
-	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.  Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole								
ŀ	- 100 =	0 /50 =	<del> </del>	0	<del></del>	0.00	\$ \$0.00		
3	Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).						\$ \$130.00	· · · · · · · · · · · · · · · · · · ·	
I	CLAIMS	NUMBER F	·	NUMBER EXTRA	RATE				
ŀ	Total claims		- 20 =	0	x \$5	0.00	\$ \$0.00		
r	Independent claim	s	- 3=	0	x \$20	0.00	\$ \$0.00		
ľ	MULTIPLE DEPENDENT CLAIMS (if applicable)						\$ \$0.00		
	TOTAL OF ABOVE CALCULATIONS =						\$ \$130.00		
Ì	Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.					\$ \$65.00			
Ī	SUBTOTAL =					\$ \$65.00			
ľ	Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$ \$0.00			
ſ	TOTAL NATIONAL FEE =					\$ \$65.00			
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +					\$ \$0.00			
ľ	MKAYPAGH 0000014	KAYPAGH 00000146 10563204 TOTAL FEES ENCLOSED:						\$ \$65.00	
7	65.00 OP					Amount to be	S		

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please charge my Deposit Account No. in the amount of \$ to cover A duplicate copy of this sheet is enclosed.	the above fees.									
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any control to Deposit Account No. 50-1619 . A duplicate copy of this sheet is enclosed.	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No50-1619 A duplicate copy of this sheet is enclosed.									
Fees are to be charged to a credit card. <b>WARNING</b> : Information on this form may become public. <b>Credit card</b> information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO:										
Jane Massey Licata, Reg. No. 32,257 SIGNATURE										
Kathleen A. Tyrrell, Reg. No. 38,350 Licata & Tyrrell P.C.  Kathleen A. Tyrrell	Kathleen A. Tyrrell									
66 E. Main Street  NAME	NAME									
Marlton, New Jersey 08053 38,350	38,350									
Telephone: (856) 810-1515 REGISTRATION NUMBER	REGISTRATION NUMBER									
Facsimile: (856) 810-1454  July 10, 2006	July 10, 2006									
DATE										



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. Stanislaw Urbaniak 10/563,204 ABLE0032US.NP INTERNATIONAL APPLICATION NO. PCT/GB04/02909 **Docket System** I.A. FILING DATE 26259 PRIORITY DATE Status Report 07/05/2004 07/04/2003

LICATLA & TYRRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053

Docket Book

CONFIRMATION NO. 6475 371 FORMALITIES LETTER \*OC000000018731701\*

Date Mailed: 05/10/2006 1110706 1110106

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 01/03/2006
- Copy of the International Search Report filed on 01/03/2006
- Copy of IPE Report filed on 01/03/2006
- Preliminary Amendments filed on 01/03/2006
- Information Disclosure Statements filed on 01/03/2006
- U.S. Basic National Fees filed on 01/03/2006
- Priority Documents filed on 01/03/2006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27. must be submitted with the missing items identified in this letter.

#### SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

### • \$65 Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO. INTERNATIONAL APPLICATION NO. ATTY. DOCKET NO.

10/563,204 PCT/GB04/02909 ABLE0032US.NP

FORM PCT/DO/EO/905 (371 Formalities Notice)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ABLE0032US.NP

Inventors: Urbaniak et al.

Serial No.: 10/563,204

Filing Date: Not yet assigned

Examiner: Not yet assigned

Customer No.: 26259

Group Art Unit: Not yet assigned

Confirmation No.: 6475

Title: Pharmaceutical Compositions comprising an

Epitope of Platelet GPIIIA Protein

"Express Mail" Label No. EV 361212537 US Date of Deposit <u>July 10, 2006</u>

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1459.

By <u>Martilla Martines</u>
Typed Name: Kathleen A. Typell, Reg/No. 38,350

Commissioner for Patents Mail Stop Sequence

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

# RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In response to the "Notification of Missing Requirements under 35 U.S.C. 371" dated May 10, 2006, a response to which is due July 10, 2006, enclosed herewith for filing is:

- 1) The original Combined Declaration and Power of Attorney Form, executed by the inventors. An unexecuted copy of this document, attached to the above-identified specification, was filed by Express Mail No. EV626224885US on January 3, 2006;
  - 2) Paper copy of amended Sequence Listing;
- 3) Copy of a computer readable form of the amended Sequence Listing;
- 4) Amendment under 37 C.F.R. 1.825 directing entry of the Sequence Listing into the record; and
- 5) Statement to Support Filing and Submission in Accordance with 37 C.F.R. 1.821 through 1.825
  - ( ) Other:
  - ( ) Associate Power of Attorney Form
- (X) Small entity status of this application has been established on January 3, 2006.
- ( ) A Verified Statement Claiming Small Entity Status Under 37 C.F.R 1.9 and 1.27.
- (X) Credit Card Payment Form in the amount of \$65.00 is attached to cover the surcharge. Please charge any deficiency or credit and overpayment to Deposit Account No. 50-1619.

This sheet is attached in duplicate.

Respectfully submitted,

Registration No. 38/350

Date: <u>July 10, 2006</u>

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515